Parkman Healthcare Partners LLC has acquired a 5.2% stake in Aligos Therapeutics, signaling increased investment interest in the biotech sector.
| Name | Aligos Therapeutics, Inc. |
|---|---|
| CIK | 0001799448 |
| Tickers | ALGS |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company |
| SIC | 2836 Biological Products, (No Diagnostic Substances) |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (800) 466-6059 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Parkman Healthcare Partners LLC has acquired a 5.2% stake in Aligos Therapeutics, signaling increased investment interest in the biotech sector.
Aligos Therapeutics, Inc. releases its Q3 financial report, highlighting key developments and ongoing projects in the biotechnology sector.
Aligos Therapeutics shares third-quarter results, showing reduced losses and ongoing clinical progress in hepatitis B treatments.
350 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001172661-26-005360 | 005-91770 | 261561464 | 34 | 11067 | |||
| 2026-11-13 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-007697 | 005-91770 | 261550664 | 34 | 21568 | |||
| 2026-11-06 | 10-Q | 10-Q | 0001193125-26-450798 | 001-39617 | 261529445 | 34 | 10361337 | 1 | 1 | |
| 2026-11-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-007214 | 001-39617 | 261529412 | 34 | 263009 | 1 | 1 |
| 2026-09-15 | 8-K | 8-K | 1.01 | 0001193125-26-391880 | 001-39617 | 261380780 | 34 | 141244 | 1 | 1 |
| 2026-08-06 | S-8 | S-8 | 0001193125-26-337937 | 333-298052 | 261248801 | 33 | 218258 | 1 | 1 | |
| 2026-08-06 | 10-Q | 10-Q | 0001193125-26-336851 | 001-39617 | 261246153 | 34 | 10162624 | 1 | 1 | |
| 2026-08-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-005294 | 001-39617 | 261246101 | 34 | 269853 | 1 | 1 |
| 2026-06-29 | 4 | xslF345X06/form4.xml | 0001610717-26-000305 | 5446 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4.xml | 0001610717-26-000304 | 5449 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4.xml | 0001610717-26-000303 | 5436 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4.xml | 0001610717-26-000302 | 5415 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4.xml | 0001610717-26-000301 | 5456 | ||||||
| 2026-06-29 | 4 | xslF345X06/form4.xml | 0001610717-26-000300 | 5413 | ||||||
| 2026-06-26 | 8-K | 8-K | 5.02,5.07,9.01 | 0001193125-26-285426 | 001-39617 | 261128941 | 34 | 171496 | 1 | 1 |
| 2026-06-24 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0001193125-26-281134 | 005-91770 | 261116233 | 34 | 12943 | |||
| 2026-05-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-226938 | 005-91770 | 26988379 | 34 | 7177 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-003231 | 005-91770 | 26982817 | 34 | 9263 | |||
| 2026-05-07 | 10-Q | 10-Q | 0001193125-26-212001 | 001-39617 | 26953684 | 34 | 8168761 | 1 | 1 | |
| 2026-05-07 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-003156 | 001-39617 | 26953211 | 34 | 256809 | 1 | 1 |
| 2026-04-29 | DEFA14A | DEFA14A | 0001193125-26-191940 | 001-39617 | 26916887 | 34 | 542146 | |||
| 2026-04-29 | ARS | ARS | 0001193125-26-191897 | 001-39617 | 26916682 | 34 | 1599365 | |||
| 2026-04-29 | DEF 14A | DEF 14A | 0001193125-26-191843 | 001-39617 | 26916565 | 34 | 2759384 | 1 | 1 | |
| 2026-04-21 | 8-K | 8-K | 1.01 | 0001193125-26-166987 | 001-39617 | 26879979 | 34 | 152686 | 1 | 1 |
| 2026-04-14 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-154927 | 001-39617 | 26861021 | 34 | 169649 | 1 | 1 |
| 2026-03-11 | 4 | xslF345X05/form4.xml | 0001610717-26-000095 | 5506 | ||||||
| 2026-03-11 | 4 | xslF345X05/form4.xml | 0001610717-26-000094 | 5435 | ||||||
| 2026-03-11 | 4 | xslF345X05/form4.xml | 0001610717-26-000093 | 5482 | ||||||
| 2026-03-11 | 4 | xslF345X05/form4.xml | 0001610717-26-000092 | 5316 | ||||||
| 2026-03-05 | S-8 | S-8 | 0001193125-26-092647 | 333-294035 | 26724276 | 33 | 208350 | 1 | 1 | |
| 2026-03-05 | 10-K | 10-K | 0001193125-26-092614 | 001-39617 | 26724251 | 34 | 14406492 | 1 | 1 | |
| 2026-03-05 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-26-001340 | 001-39617 | 26724242 | 34 | 280714 | 1 | 1 |
| 2026-02-19 | 3 | xslF345X02/form3.xml | 0001610717-26-000055 | 15217 | ||||||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-26-001065 | 005-91770 | 26640208 | 34 | 9009 | |||
| 2026-02-11 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-26-001502 | 005-91770 | 26621313 | 34 | 9536 | |||
| 2026-02-04 | 8-K | 8-K | 5.02 | 0001193125-26-037558 | 001-39617 | 26598187 | 34 | 137979 | 1 | 1 |
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-005026 | 005-91770 | 251486470 | 34 | 8996 | |||
| 2025-11-06 | 10-Q | 10-Q | 0001193125-25-268203 | 001-39617 | 251456393 | 34 | 9287937 | 1 | 1 | |
| 2025-11-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-007075 | 001-39617 | 251456364 | 34 | 273843 | 1 | 1 |
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-003590 | 005-91770 | 251216070 | 34 | 8785 | |||
| 2025-08-13 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-011951 | 005-91770 | 251210502 | 34 | 9401 | |||
| 2025-08-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-003496 | 005-91770 | 251204311 | 34 | 13126 | |||
| 2025-08-06 | S-8 | S-8 | 0001193125-25-174519 | 333-289307 | 251190221 | 33 | 212280 | 1 | 1 | |
| 2025-08-06 | 10-Q | 10-Q | 0000950170-25-104042 | 001-39617 | 251189726 | 34 | 9751079 | 1 | 1 | |
| 2025-08-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-005116 | 001-39617 | 251189511 | 34 | 283307 | 1 | 1 |
| 2025-07-18 | 4 | xslF345X05/form4.xml | 0001610717-25-000290 | 5317 | ||||||
| 2025-07-18 | 4 | xslF345X05/form4.xml | 0001610717-25-000289 | 5507 | ||||||
| 2025-07-18 | 4 | xslF345X05/form4.xml | 0001610717-25-000286 | 5483 | ||||||
| 2025-06-26 | 4 | xslF345X05/form4.xml | 0001610717-25-000259 | 5300 | ||||||
| 2025-06-26 | 4 | xslF345X05/form4.xml | 0001610717-25-000258 | 5279 | ||||||
| 2025-06-26 | 4 | xslF345X05/form4.xml | 0001610717-25-000257 | 5277 | ||||||
| 2025-06-26 | 4 | xslF345X05/form4.xml | 0001610717-25-000256 | 5310 | ||||||
| 2025-06-26 | 4 | xslF345X05/form4.xml | 0001610717-25-000255 | 5313 | ||||||
| 2025-06-26 | 4 | xslF345X05/form4.xml | 0001610717-25-000254 | 5300 | ||||||
| 2025-06-26 | 8-K | 8-K | 5.02,5.03,5.07,9.01 | 0001193125-25-148905 | 001-39617 | 251080446 | 34 | 193499 | 1 | 1 |
| 2025-05-15 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-002361 | 005-91770 | 25953669 | 34 | 10426 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000935836-25-000358 | 005-91770 | 25951244 | 34 | 16739 | |||
| 2025-05-15 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-002357 | 005-91770 | 25949349 | 34 | 8670 | |||
| 2025-05-06 | 10-Q | 10-Q | 0000950170-25-063983 | 001-39617 | 25915358 | 34 | 8624265 | 1 | 1 | |
| 2025-05-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-002781 | 001-39617 | 25915300 | 34 | 278896 | 1 | 1 |
| 2025-04-28 | DEFA14A | DEFA14A | 0001193125-25-100542 | 001-39617 | 25880560 | 34 | 713938 | |||
| 2025-04-28 | ARS | ARS | 0001193125-25-100516 | 001-39617 | 25880469 | 34 | 5863119 | |||
| 2025-04-28 | DEF 14A | DEF 14A | 0001193125-25-100453 | 001-39617 | 25880257 | 34 | 2317178 | 1 | 1 | |
| 2025-04-16 | PRE 14A | PRE 14A | 0001193125-25-082777 | 001-39617 | 25842700 | 34 | 2325060 | 1 | 1 | |
| 2025-04-03 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-000975 | 333-286168 | 25811902 | 33 | 1772 | ||
| 2025-04-03 | 424B3 | 424B3 | 0001193125-25-072387 | 333-286168 | 25809839 | 33 | 226591 | |||
| 2025-04-01 | CORRESP | filename1.htm | 0001193125-25-070406 | 7438 | ||||||
| 2025-04-01 | UPLOAD | filename1.pdf | 0000000000-25-003496 | 333-286168 | 40172 | |||||
| 2025-03-27 | S-3 | S-3 | 0001193125-25-065499 | 333-286168 | 25779289 | 33 | 336295 | |||
| 2025-03-12 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0000950170-25-038262 | 005-91770 | 25733467 | 34 | 8340 | |||
| 2025-03-10 | S-8 | S-8 | 0001193125-25-050851 | 333-285677 | 25723585 | 33 | 99820 | |||
| 2025-03-10 | 10-K | 10-K | 0000950170-25-035929 | 001-39617 | 25722214 | 34 | 17752339 | 1 | 1 | |
| 2025-03-10 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-25-001352 | 001-39617 | 25722194 | 34 | 288985 | 1 | 1 |
| 2025-03-04 | 4 | xslF345X05/form4.xml | 0001610717-25-000046 | 5328 | ||||||
| 2025-03-04 | 4 | xslF345X05/form4.xml | 0001610717-25-000045 | 5520 | ||||||
| 2025-03-04 | 4 | xslF345X05/form4.xml | 0001610717-25-000044 | 5509 | ||||||
| 2025-02-28 | D | xslFormDX01/primary_doc.xml | 06b | 0000950123-25-002925 | 021-539576 | 25690234 | 33 | 15712 | ||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001172661-25-001230 | 005-91770 | 25630416 | 34 | 10648 | |||
| 2025-02-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-000862 | 005-91770 | 25612612 | 34 | 12469 | |||
| 2025-02-12 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0001193125-25-024838 | 001-39617 | 25612197 | 34 | 1006779 | 1 | 1 |
| 2025-02-03 | 8-K | 8-K | 5.02 | 0001193125-25-019256 | 001-39617 | 25582445 | 34 | 151335 | 1 | 1 |
| 2024-11-18 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-11-18 16:00:00 | 9999999995-24-003508 | 333-283041 | 241473217 | 33 | 1780 | ||
| 2024-11-14 | SC 13G/A | AMENDMENT NO. 1 TO SCHEDULE 13G | 0001213900-24-098622 | 005-91770 | 241465113 | 34 | 88154 | |||
| 2024-11-14 | SC 13G/A | algs13ga3.htm | 0000935836-24-000723 | 005-91770 | 241464949 | 34 | 48482 | |||
| 2024-11-14 | SC 13G/A | armistice-algs093024a1.htm | 0001172661-24-005305 | 005-91770 | 241464040 | 34 | 90462 | |||
| 2024-11-14 | SC 13G/A | alyeska-algs093024a1.htm | 0001172661-24-005266 | 005-91770 | 241463468 | 34 | 106168 | |||
| 2024-11-14 | SC 13G/A | ALIGOS THERAPEUTICS, INC. | 0000902664-24-006624 | 005-91770 | 241463364 | 34 | 59362 | |||
| 2024-11-14 | CORRESP | filename1.htm | 0001193125-24-258591 | 8261 | ||||||
| 2024-11-13 | UPLOAD | filename1.pdf | 0000000000-24-012567 | 333-283041 | 40192 | |||||
| 2024-11-12 | SC 13G | ALIGOS THERAPEUTICS, INC. | 0000902664-24-006398 | 005-91770 | 241444193 | 34 | 75044 | |||
| 2024-11-06 | S-8 | S-8 | 0001193125-24-252201 | 333-283042 | 241432256 | 33 | 107115 | |||
| 2024-11-06 | S-3 | S-3 | 0001193125-24-252199 | 333-283041 | 241432201 | 33 | 767921 | |||
| 2024-11-06 | 10-Q | 10-Q | 0000950170-24-122371 | 001-39617 | 241431420 | 34 | 15432761 | 1 | 1 | |
| 2024-11-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-006057 | 001-39617 | 241430868 | 34 | 274329 | 1 | 1 |
| 2024-10-10 | 4 | xslF345X05/form4.xml | 0001610717-24-000503 | 5367 | ||||||
| 2024-09-26 | 3 | xslF345X02/form3.xml | 0001610717-24-000495 | 13821 | ||||||
| 2024-09-12 | SC 13G | ALGS_SC13G.htm | 0001783647-24-000001 | 005-91770 | 241295218 | 34 | 95920 | |||
| 2024-09-06 | 4 | xslF345X05/form4.xml | 0001610717-24-000466 | 5457 | ||||||
| 2024-09-06 | 4 | xslF345X05/form4.xml | 0001610717-24-000465 | 5332 | ||||||
| 2024-09-06 | 4 | xslF345X05/form4.xml | 0001610717-24-000464 | 5521 | ||||||
| 2024-09-05 | 8-K | 8-K | 8.01 | 0001193125-24-214188 | 001-39617 | 241281447 | 34 | 148602 | 1 | 1 |
| 2024-08-19 | 8-K | 8-K | 3.03,5.03,9.01 | 0001193125-24-202813 | 001-39617 | 241220452 | 34 | 177901 | 1 | 1 |
| 2024-08-09 | 4 | xslF345X05/form4.xml | 0001610717-24-000423 | 5311 | ||||||
| 2024-08-09 | 4 | xslF345X05/form4.xml | 0001610717-24-000422 | 5308 | ||||||
| 2024-08-09 | 3 | xslF345X02/form3.xml | 0001610717-24-000421 | 13773 | ||||||
| 2024-08-09 | 3 | xslF345X02/form3.xml | 0001610717-24-000419 | 13733 | ||||||
| 2024-08-08 | 8-K | 8-K | 5.02 | 0001193125-24-196966 | 001-39617 | 241188398 | 34 | 152059 | 1 | 1 |
| 2024-08-06 | 10-Q | 10-Q | 0000950170-24-091828 | 001-39617 | 241179425 | 34 | 8689850 | 1 | 1 | |
| 2024-08-06 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-004482 | 001-39617 | 241179111 | 34 | 273583 | 1 | 1 |
| 2024-06-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000372 | 5273 | ||||||
| 2024-06-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000371 | 5310 | ||||||
| 2024-06-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000370 | 5289 | ||||||
| 2024-06-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000369 | 5310 | ||||||
| 2024-06-28 | 8-K | 8-K | 5.02,5.03,5.07,9.01 | 0001193125-24-172218 | 001-39617 | 241085434 | 34 | 197468 | 1 | 1 |
| 2024-05-31 | 8-K | 8-K | 3.01 | 0001193125-24-151729 | 001-39617 | 241009652 | 34 | 148650 | 1 | 1 |
| 2024-05-22 | 8-K | 8-K | 3.01,5.02 | 0001193125-24-144929 | 001-39617 | 24973193 | 34 | 151005 | 1 | 1 |
| 2024-05-15 | 8-K | 8-K | 5.02 | 0001193125-24-139476 | 001-39617 | 24952317 | 34 | 146881 | 1 | 1 |
| 2024-05-07 | 10-Q | 10-Q | 0000950170-24-054497 | 001-39617 | 24921997 | 34 | 7563312 | 1 | 1 | |
| 2024-05-07 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-002612 | 001-39617 | 24921757 | 34 | 258543 | 1 | 1 |
| 2024-04-29 | ARS | ARS | 0001193125-24-122248 | 001-39617 | 24890782 | 34 | 24724110 | |||
| 2024-04-29 | DEFA14A | DEFA14A | 0001193125-24-122208 | 001-39617 | 24890562 | 34 | 736597 | |||
| 2024-04-29 | DEF 14A | DEF 14A | 0001193125-24-122181 | 001-39617 | 24890431 | 34 | 1380166 | |||
| 2024-04-16 | PRE 14A | PRE 14A | 0001193125-24-097951 | 001-39617 | 24848803 | 34 | 1379825 | |||
| 2024-03-12 | S-8 | S-8 | 0001193125-24-065970 | 333-277860 | 24742968 | 33 | 90600 | |||
| 2024-03-12 | 10-K | 10-K | 0000950170-24-029953 | 001-39617 | 24742261 | 34 | 12518237 | 1 | 1 | |
| 2024-03-12 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-24-001294 | 001-39617 | 24742096 | 34 | 280168 | 1 | 1 |
| 2024-03-04 | 4 | xslF345X05/form4.xml | 0001610717-24-000124 | 5452 | ||||||
| 2024-03-04 | 4 | xslF345X05/form4.xml | 0001610717-24-000123 | 5454 | ||||||
| 2024-03-04 | 4 | xslF345X05/form4.xml | 0001610717-24-000122 | 5515 | ||||||
| 2024-03-04 | 4 | xslF345X05/form4.xml | 0001610717-24-000121 | 5329 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000102 | 7616 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000101 | 7632 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000100 | 17171 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000099 | 17173 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000098 | 17056 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000097 | 17237 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000096 | 7645 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000095 | 7653 | ||||||
| 2024-02-28 | 4 | xslF345X05/form4.xml | 0001610717-24-000094 | 7657 | ||||||
| 2024-02-28 | 8-K | 8-K | 5.02 | 0001193125-24-050987 | 001-39617 | 24697278 | 34 | 155701 | 1 | 1 |
| 2024-02-28 | SC TO-I/A | SC TO-I/A | 0001193125-24-050959 | 005-91770 | 24697205 | 34 | 29277 | |||
| 2024-02-14 | SC 13G/A | algs13ga2.htm | 0000935836-24-000204 | 005-91770 | 24640327 | 34 | 48519 | |||
| 2024-02-14 | SC 13G/A | ALIGOS THERAPEUTICS, INC. | 0000902664-24-001727 | 005-91770 | 24639380 | 34 | 59264 | |||
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001104659-24-023723 | 005-91770 | 24638758 | 34 | 92412 | |||
| 2024-02-14 | SC 13G/A | AMENDMENT NO. 2 | 0001214659-24-002858 | 005-91770 | 24637380 | 34 | 85225 | |||
| 2024-02-14 | SC 13G | armistice-algs123123.htm | 0001172661-24-001312 | 005-91770 | 24636762 | 34 | 90589 | |||
| 2024-02-14 | SC 13G | alyeska-algs123123.htm | 0001172661-24-001196 | 005-91770 | 24635742 | 34 | 106733 | |||
| 2024-02-08 | SC 13D/A | SC 13D/A | 0001193125-24-028548 | 005-91770 | 24610427 | 34 | 118037 | |||
| 2024-01-30 | SC TO-I | SC TO-I | 0001193125-24-018712 | 005-91770 | 24575794 | 34 | 10856143 | |||
| 2024-01-25 | SC TO-C | SC TO-C | 0001193125-24-014780 | 005-91770 | 24558487 | 34 | 28903 | |||
| 2024-01-25 | 8-K | 8-K | 8.01,9.01 | 0001193125-24-014769 | 001-39617 | 24558477 | 34 | 163682 | 1 | 1 |
| 2023-11-28 | 424B3 | 424B3 | 0001193125-23-284262 | 333-275636 | 231446284 | 33 | 209063 | |||
| 2023-11-27 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-11-27 16:00:00 | 9999999995-23-003451 | 333-275636 | 231441763 | 33 | 1731 | ||
| 2023-11-22 | CORRESP | filename1.htm | 0001193125-23-282242 | 7642 | ||||||
| 2023-11-22 | 8-K | 8-K | 5.02 | 0001193125-23-282236 | 001-39617 | 231433418 | 34 | 147145 | 1 | 1 |
| 2023-11-21 | UPLOAD | filename1.pdf | 0000000000-23-012755 | 40374 | ||||||
| 2023-11-17 | S-3 | S-3 | 0001193125-23-279833 | 333-275636 | 231419391 | 33 | 308654 | |||
| 2023-11-15 | 8-K | 8-K | 5.02 | 0001193125-23-277877 | 001-39617 | 231410491 | 34 | 141822 | 1 | 1 |
| 2023-11-07 | SC 13G/A | SC 13G/A | 0001104659-23-115332 | 005-91770 | 231385100 | 34 | 64115 | |||
| 2023-11-07 | 3 | OWNERSHIP DOCUMENT | 0001104659-23-115329 | 7920 | ||||||
| 2023-11-07 | D | xslFormDX01/primary_doc.xml | 06b | 0001567619-23-007642 | 021-496669 | 231382513 | 33 | 15235 | ||
| 2023-11-06 | SC 13D | SC 13D | 0001193125-23-271361 | 005-91770 | 231379961 | 34 | 54661 | |||
| 2023-11-02 | 10-Q | 10-Q | 0000950170-23-058256 | 001-39617 | 231372729 | 34 | 8594788 | 1 | 1 | |
| 2023-11-02 | SC 13G | deeptrack-algs102323.htm | 0001172661-23-003592 | 005-91770 | 231372295 | 34 | 105181 | |||
| 2023-11-02 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-006671 | 001-39617 | 231372179 | 34 | 273528 | 1 | 1 |
| 2023-10-27 | 4 | xslF345X05/form4.xml | 0001610717-23-000320 | 7475 | ||||||
| 2023-10-27 | 4 | xslF345X05/form4.xml | 0001610717-23-000319 | 9514 | ||||||
| 2023-10-27 | 4 | xslF345X05/form4.xml | 0001610717-23-000318 | 6218 | ||||||
| 2023-10-25 | 8-K | 8-K | 1.01,3.02,9.01 | 0001193125-23-263158 | 001-39617 | 231346676 | 34 | 617726 | 1 | 1 |
| 2023-10-18 | 8-K | 8-K | 8.01 | 0001193125-23-258115 | 001-39617 | 231331005 | 34 | 147903 | 1 | 1 |
| 2023-09-12 | 4 | xslF345X05/form4.xml | 0001610717-23-000277 | 5368 | ||||||
| 2023-09-12 | 4 | xslF345X05/form4.xml | 0001610717-23-000276 | 5411 | ||||||
| 2023-09-12 | 4 | xslF345X05/form4.xml | 0001610717-23-000275 | 5405 | ||||||
| 2023-09-12 | 4 | xslF345X05/form4.xml | 0001610717-23-000274 | 5431 | ||||||
| 2023-09-12 | 4 | xslF345X05/form4.xml | 0001610717-23-000273 | 5203 | ||||||
| 2023-09-07 | 8-K | 8-K | 3.01 | 0001193125-23-230611 | 001-39617 | 231242217 | 34 | 149558 | 1 | 1 |
| 2023-08-03 | 10-Q | 10-Q | 0000950170-23-038045 | 001-39617 | 231140397 | 34 | 9155603 | 1 | 1 | |
| 2023-08-03 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-004975 | 001-39617 | 231139856 | 34 | 283101 | 1 | 1 |
| 2023-08-01 | 8-K | 8-K | 8.01 | 0001193125-23-200617 | 001-39617 | 231132502 | 34 | 149502 | 1 | 1 |
| 2023-07-25 | 8-K | 8-K | 5.07 | 0001193125-23-193424 | 001-39617 | 231108554 | 34 | 154961 | 1 | 1 |
| 2023-07-21 | 4 | xslF345X05/form4.xml | 0001610717-23-000217 | 5222 | ||||||
| 2023-07-21 | 4 | xslF345X05/form4.xml | 0001610717-23-000216 | 5214 | ||||||
| 2023-07-21 | 4 | xslF345X05/form4.xml | 0001610717-23-000213 | 5177 | ||||||
| 2023-07-21 | 4 | xslF345X05/form4.xml | 0001610717-23-000212 | 5201 | ||||||
| 2023-07-21 | 4 | xslF345X05/form4.xml | 0001610717-23-000210 | 5222 | ||||||
| 2023-06-02 | DEFR14A | DEFR14A | 0001193125-23-159828 | 001-39617 | 23988677 | 34 | 12713 | |||
| 2023-05-04 | 10-Q | 10-Q | 0000950170-23-017890 | 001-39617 | 23889036 | 34 | 7998135 | 1 | 1 | |
| 2023-05-04 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-002889 | 001-39617 | 23888609 | 34 | 261889 | 1 | 1 |
| 2023-04-28 | ARS | ARS | 0001193125-23-127488 | 001-39617 | 23867849 | 34 | 13106670 | |||
| 2023-04-28 | DEFA14A | DEFA14A | 0001193125-23-127438 | 001-39617 | 23867761 | 34 | 347891 | |||
| 2023-04-28 | DEF 14A | DEF 14A | 0001193125-23-127382 | 001-39617 | 23867558 | 34 | 704154 | |||
| 2023-03-17 | 4 | FORM 4 | 0001567619-23-005257 | 5664 | ||||||
| 2023-03-17 | 4 | FORM 4 | 0001567619-23-005256 | 5730 | ||||||
| 2023-03-17 | 4 | FORM 4 | 0001567619-23-005255 | 5722 | ||||||
| 2023-03-17 | 4 | FORM 4 | 0001567619-23-005254 | 5690 | ||||||
| 2023-03-17 | 4 | FORM 4 | 0001567619-23-005252 | 5656 | ||||||
| 2023-03-17 | 4 | FORM 4 | 0001567619-23-005251 | 5504 | ||||||
| 2023-03-09 | S-8 | S-8 | 0001193125-23-066188 | 333-270417 | 23720329 | 33 | 86481 | |||
| 2023-03-09 | 10-K | 10-K | 0000950170-23-007033 | 001-39617 | 23719911 | 34 | 15094231 | 1 | 1 | |
| 2023-03-09 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-23-001548 | 001-39617 | 23719717 | 34 | 280878 | 1 | 1 |
| 2023-02-14 | SC 13G/A | ALIGOS THERAPEUTICS, INC. | 0000902664-23-001809 | 005-91770 | 23629231 | 34 | 60275 | |||
| 2023-02-14 | SC 13G/A | AMENDMENT NO. 1 | 0001214659-23-002389 | 005-91770 | 23628390 | 34 | 82947 | |||
| 2023-02-13 | SC 13G/A | algs13ga.htm | 0000935836-23-000115 | 005-91770 | 23614872 | 34 | 47099 | |||
| 2023-02-09 | SC 13G/A | JHG PLC OWNS <5% | 0001274173-23-000004 | 005-91770 | 23601916 | 34 | 10049 | |||
| 2023-02-08 | SC 13G/A | SC 13G/A | 0001193125-23-028518 | 005-91770 | 23599866 | 34 | 37375 | |||
| 2022-12-27 | SC 13G | r1221221sc13g.htm | 0001214659-22-015381 | 005-91770 | 221490982 | 34 | 91111 | |||
| 2022-12-27 | UPLOAD | filename1.pdf | 0000000000-22-013927 | 39659 | ||||||
| 2022-12-22 | CORRESP | filename1.htm | 0001193125-22-311384 | 65449 | ||||||
| 2022-12-08 | UPLOAD | filename1.pdf | 0000000000-22-013221 | 47611 | ||||||
| 2022-11-02 | 10-Q | 10-Q | 0000950170-22-021248 | 001-39617 | 221354271 | 34 | 8914599 | 1 | 1 | |
| 2022-11-02 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-007002 | 001-39617 | 221354004 | 34 | 280287 | 1 | 1 |
| 2022-08-04 | 10-Q | 10-Q | 0000950170-22-014815 | 001-39617 | 221137309 | 34 | 8552903 | 1 | 1 | |
| 2022-08-04 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-005357 | 001-39617 | 221136501 | 34 | 286427 | 1 | 1 |
| 2022-07-11 | 4 | FORM 4 | 0001567619-22-013870 | 5584 | ||||||
| 2022-07-11 | 4 | FORM 4 | 0001567619-22-013869 | 5689 | ||||||
| 2022-07-11 | 4 | FORM 4 | 0001567619-22-013868 | 5721 | ||||||
| 2022-07-11 | 4 | FORM 4 | 0001567619-22-013867 | 5655 | ||||||
| 2022-07-11 | 4 | FORM 4 | 0001567619-22-013866 | 5503 | ||||||
| 2022-07-11 | 4 | FORM 4 | 0001567619-22-013865 | 5729 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001567619-22-013392 | 5536 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001567619-22-013391 | 5529 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001567619-22-013390 | 5542 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001567619-22-013389 | 5558 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001567619-22-013388 | 5566 | ||||||
| 2022-06-27 | 4 | FORM 4 | 0001567619-22-013387 | 5565 | ||||||
| 2022-06-27 | 8-K | 8-K | 5.07 | 0001193125-22-182802 | 001-39617 | 221044502 | 34 | 153160 | 1 | 1 |
| 2022-05-06 | 3 | FORM 3 | 0001567619-22-009672 | 16694 | ||||||
| 2022-05-04 | 10-Q | 10-Q | 0000950170-22-007407 | 001-39617 | 22892006 | 34 | 7628414 | 1 | 1 | |
| 2022-05-04 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-003216 | 001-39617 | 22891505 | 34 | 263756 | 1 | 1 |
| 2022-04-29 | DEFA14A | DEFA14A | 0001193125-22-134018 | 001-39617 | 22876400 | 34 | 1107603 | |||
| 2022-04-29 | DEF 14A | DEF 14A | 0001193125-22-129730 | 001-39617 | 22869852 | 34 | 709920 | |||
| 2022-03-30 | 8-K | 8-K | 8.01 | 0001193125-22-088448 | 001-39617 | 22783010 | 34 | 146174 | 1 | 1 |
| 2022-03-22 | 8-K | 8-K | 8.01 | 0001193125-22-081126 | 001-39617 | 22757233 | 34 | 150824 | 1 | 1 |
| 2022-03-10 | S-8 | S-8 | 0001193125-22-072061 | 333-263447 | 22729909 | 33 | 83320 | |||
| 2022-03-10 | 10-K | 10-K | 0000950170-22-003365 | 001-39617 | 22729198 | 34 | 23226555 | 1 | 1 | |
| 2022-03-10 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-22-001773 | 001-39617 | 22729052 | 34 | 290307 | 1 | 1 |
| 2022-02-14 | SC 13G | aligostherapeutics13g.htm | 0000935836-22-000180 | 005-91770 | 22634014 | 34 | 47056 | |||
| 2022-02-14 | SC 13G/A | aligos13ga1.htm | 0000935836-22-000175 | 005-91770 | 22633031 | 34 | 59889 | |||
| 2022-02-14 | SC 13G | SCHEDULE 13G | 0001104659-22-022802 | 005-91770 | 22632001 | 34 | 88070 | |||
| 2022-02-14 | SC 13G/A | ALIGOS THERAPEUTICS, INC. | 0000902664-22-001723 | 005-91770 | 22631718 | 34 | 60310 | |||
| 2022-02-14 | SC 13G | JANUS HENDERSON GROUP PLC OWNS 5.7% OF ALIGOS CIK 0001799448 | 0001274173-22-000082 | 005-91770 | 22625509 | 34 | 10591 | |||
| 2022-02-10 | SC 13G/A | SC 13G/A | 0001193125-22-034471 | 005-91770 | 22614227 | 34 | 42365 | |||
| 2022-02-10 | SC 13G/A | SC 13G/A | 0001193125-22-034455 | 005-91770 | 22614110 | 34 | 39618 | |||
| 2022-02-10 | SC 13G/A | SEC SCHEDULE 13G | 0000902219-22-000013 | 005-91770 | 22609601 | 34 | 33200 | |||
| 2022-02-08 | 4 | FORM 4 | 0001567619-22-002893 | 8058 | ||||||
| 2022-02-08 | 4 | FORM 4 | 0001567619-22-002892 | 7829 | ||||||
| 2022-02-08 | 4 | FORM 4 | 0001567619-22-002891 | 8050 | ||||||
| 2022-02-08 | 4 | FORM 4 | 0001567619-22-002890 | 8018 | ||||||
| 2022-02-08 | 4 | FORM 4 | 0001567619-22-002889 | 7981 | ||||||
| 2022-02-04 | SC 13G/A | SEC SCHEDULE 13G | 0001678858-22-000101 | 005-91770 | 22591222 | 34 | 37587 | |||
| 2022-02-04 | SC 13G/A | SEC SCHEDULE 13G | 0001678858-22-000043 | 005-91770 | 22591131 | 34 | 18941 | |||
| 2022-01-31 | SC 13D/A | SC 13D/A | 0001193125-22-023399 | 005-91770 | 22574353 | 34 | 62662 | |||
| 2022-01-06 | 8-K | 8-K | 8.01 | 0001193125-22-003165 | 001-39617 | 22513668 | 34 | 146405 | 1 | 1 |
| 2021-11-19 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2021-11-19 16:00:00 | 9999999995-21-004423 | 333-260774 | 211430044 | 33 | 1731 | ||
| 2021-11-18 | 4 | FORM 4 | 0001567619-21-020770 | 5554 | ||||||
| 2021-11-18 | 3 | FORM 3 | 0001567619-21-020768 | 11742 | ||||||
| 2021-11-18 | 8-K | 8-K | 5.02 | 0001193125-21-333831 | 001-39617 | 211424637 | 34 | 148099 | 1 | 1 |
| 2021-11-17 | CORRESP | filename1.htm | 0001193125-21-332453 | 6992 | ||||||
| 2021-11-15 | UPLOAD | filename1.pdf | 0000000000-21-013788 | 40244 | ||||||
| 2021-11-04 | S-3 | S-3 | 0001193125-21-320316 | 333-260774 | 211380906 | 33 | 1015537 | |||
| 2021-11-04 | 10-Q | 10-Q | 0001564590-21-054514 | 001-39617 | 211380400 | 34 | 9816856 | 1 | 1 | |
| 2021-11-04 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-007561 | 001-39617 | 211379959 | 34 | 283020 | 1 | 1 |
| 2021-08-13 | SC 13G | aligos13g.htm | 0000935836-21-000462 | 005-91770 | 211170903 | 34 | 60217 | |||
| 2021-08-05 | 10-Q | 10-Q | 0001564590-21-041653 | 001-39617 | 211148984 | 34 | 9754857 | 1 | 1 | |
| 2021-08-05 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-005574 | 001-39617 | 211148130 | 34 | 77670 | ||
| 2021-07-01 | 424B4 | 424B4 | 0001193125-21-206345 | 333-257466 | 211066297 | 33 | 1396656 | |||
| 2021-06-30 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2021-06-30 16:30:00 | 9999999995-21-002615 | 333-257466 | 211063881 | 33 | 1731 | ||
| 2021-06-28 | CORRESP | filename1.htm | 0001193125-21-202060 | 10489 | ||||||
| 2021-06-28 | CORRESP | filename1.htm | 0001193125-21-202052 | 8447 | ||||||
| 2021-06-28 | S-1 | S-1 | 0001193125-21-201893 | 333-257466 | 211053290 | 33 | 1818019 | |||
| 2021-06-24 | 8-K | 8-K | 5.07 | 0001193125-21-198812 | 001-39617 | 211043669 | 34 | 20758 | ||
| 2021-06-24 | 8-K/A | 8-K/A | 5.02 | 0001193125-21-198804 | 001-39617 | 211043632 | 34 | 17704 | ||
| 2021-06-21 | SC 13D/A | SC 13D/A | 0001193125-21-195170 | 005-91770 | 211031363 | 34 | 117734 | |||
| 2021-06-21 | SC 13D/A | SC 13D/A | 0001193125-21-195127 | 005-91770 | 211031008 | 34 | 62133 | |||
| 2021-06-17 | 4 | FORM 4 | 0001567619-21-012370 | 5551 | ||||||
| 2021-06-17 | 4 | FORM 4 | 0001567619-21-012339 | 5529 | ||||||
| 2021-06-17 | 4 | FORM 4 | 0001567619-21-012337 | 5522 | ||||||
| 2021-06-17 | 4 | FORM 4 | 0001567619-21-012335 | 5559 | ||||||
| 2021-06-15 | 4 | FORM 4 SUBMISSION | 0000899243-21-023881 | 16961 | ||||||
| 2021-06-10 | UPLOAD | filename1.pdf | 0000000000-21-007161 | 40434 | ||||||
| 2021-06-04 | DRS | filename1.htm | 0000950123-21-007570 | 377-04970 | 21997233 | 33 | 1526272 | |||
| 2021-05-10 | 10-Q | 10-Q | 0001564590-21-026071 | 001-39617 | 21907529 | 34 | 7875972 | 1 | ||
| 2021-05-10 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-003344 | 001-39617 | 21907062 | 34 | 43814 | ||
| 2021-05-03 | SC 13D/A | SC 13D/A | 0001193125-21-148141 | 005-91770 | 21884424 | 34 | 124942 | |||
| 2021-04-28 | 4 | FORM 4 SUBMISSION | 0000899243-21-017187 | 16960 | ||||||
| 2021-04-27 | 4 | FORM 4 | 0001567619-21-008646 | 5530 | ||||||
| 2021-04-27 | 3 | FORM 3 | 0001567619-21-008645 | 10949 | ||||||
| 2021-04-27 | DEFA14A | DEFA14A | 0001193125-21-134270 | 001-39617 | 21859179 | 34 | 272504 | |||
| 2021-04-27 | DEF 14A | DEF 14A | 0001193125-21-134253 | 001-39617 | 21859098 | 34 | 745325 | |||
| 2021-04-27 | 8-K | 8-K | 5.02 | 0001193125-21-134238 | 001-39617 | 21859053 | 34 | 17906 | ||
| 2021-03-23 | S-8 | S-8 | 0001193125-21-091296 | 333-254628 | 21765439 | 33 | 72929 | |||
| 2021-03-23 | 10-K | 10-K | 0001564590-21-014872 | 001-39617 | 21765071 | 34 | 16827828 | 1 | ||
| 2021-03-23 | 8-K | FORM 8-K | 2.02,9.01 | 0001171843-21-001999 | 001-39617 | 21764834 | 34 | 75928 | ||
| 2021-02-16 | SC 13G | ALIGOS THERAPEUTICS, INC. | 0000902664-21-001431 | 005-91770 | 21639100 | 34 | 61567 | |||
| 2021-02-16 | SC 13G | SC 13G | 0001104659-21-022721 | 005-91770 | 21632305 | 34 | 61716 | |||
| 2021-02-11 | SC 13G | SC 13G | 0001193125-21-038482 | 005-91770 | 21619928 | 34 | 37544 | |||
| 2021-02-11 | SC 13G | SC 13G | 0001193125-21-038470 | 005-91770 | 21619873 | 34 | 39833 | |||
| 2021-01-11 | SC 13G | SEC SCHEDULE 13G | 0000902219-21-000003 | 005-91770 | 21519504 | 34 | 37635 | |||
| 2020-12-03 | 4 | FORM 4 | 0001567619-20-020625 | 5658 | ||||||
| 2020-12-03 | 4 | FORM 4 | 0001567619-20-020624 | 5828 | ||||||
| 2020-12-03 | 4 | FORM 4 | 0001567619-20-020623 | 5618 | ||||||
| 2020-12-03 | 4 | FORM 4 | 0001567619-20-020622 | 5581 | ||||||
| 2020-12-03 | 4 | FORM 4 | 0001567619-20-020621 | 5429 | ||||||
| 2020-11-25 | 10-Q | 10-Q | 0001193125-20-303749 | 001-39617 | 201351989 | 34 | 6380784 | 1 | ||
| 2020-10-30 | SC 13D | SC 13D | 0001193125-20-282616 | 005-91770 | 201277676 | 34 | 136188 | |||
| 2020-10-28 | SC 13G | SCHEDULE 13G | 0001213900-20-033706 | 005-91770 | 201269039 | 34 | 49194 | |||
| 2020-10-22 | SC 13D | SC 13D | 0001193125-20-274431 | 005-91770 | 201255220 | 34 | 107670 | |||
| 2020-10-22 | 4 | FORM 4 SUBMISSION | 0001209191-20-055572 | 13831 | ||||||
| 2020-10-22 | 4 | FORM 4 SUBMISSION | 0001209191-20-055562 | 11266 | ||||||
| 2020-10-22 | SC 13G | SEC SCHEDULE 13G | 0001787092-20-000006 | 005-91770 | 201251998 | 34 | 19067 | |||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018012 | 25987 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018010 | 33857 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018008 | 26764 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018006 | 13927 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018004 | 15521 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018003 | 15713 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018001 | 42317 | ||||||
| 2020-10-20 | 4 | FORM 4 | 0001567619-20-018000 | 42209 | ||||||
| 2020-10-20 | S-8 | S-8 | 0001193125-20-272903 | 333-249568 | 201248663 | 33 | 110298 | |||
| 2020-10-20 | 8-K | 8-K | 5.03,8.01,9.01 | 0001193125-20-272852 | 001-39617 | 201248316 | 34 | 239932 | ||
| 2020-10-19 | 424B4 | 424B4 | 0001193125-20-272151 | 333-249077 | 201246837 | 33 | 6688981 | |||
| 2020-10-15 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2020-10-15 16:30:00 | 9999999995-20-002863 | 333-249077 | 201242688 | 33 | 1731 | ||
| 2020-10-15 | 3 | FORM 3 SUBMISSION | 0001209191-20-054973 | 5806 | ||||||
| 2020-10-15 | 3 | FORM 3 SUBMISSION | 0001209191-20-054956 | 7033 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017873 | 19257 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017872 | 15323 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017871 | 12900 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017870 | 17695 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017869 | 18230 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017868 | 15710 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017867 | 10596 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017866 | 10539 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017865 | 11383 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017864 | 11432 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017863 | 13539 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017862 | 27992 | ||||||
| 2020-10-15 | 3 | FORM 3 | 0001567619-20-017861 | 30602 | ||||||
| 2020-10-14 | CERT | 8A_Cert_ALGS.pdf | 0001354457-20-000586 | 001-39617 | 201238537 | 34 | 202428 | |||
| 2020-10-13 | CORRESP | filename1.htm | 0001193125-20-268627 | 14484 | ||||||
| 2020-10-13 | CORRESP | filename1.htm | 0001193125-20-268617 | 8946 | ||||||
| 2020-10-13 | 8-A12B | 8-A12B | 0001193125-20-268246 | 001-39617 | 201235750 | 34 | 14211 | |||
| 2020-10-09 | S-1/A | AMENDMENT NO. 1 TO FORM S-1 | 0001193125-20-267346 | 333-249077 | 201234005 | 33 | 9128976 | |||
| 2020-10-05 | SEC STAFF LETTER | filename1.pdf | 9999999997-20-004899 | 270828 | ||||||
| 2020-10-02 | CORRESP | filename1.htm | 0001193125-20-262777 | 98927 | ||||||
| 2020-09-28 | SEC STAFF LETTER | filename1.pdf | 9999999997-20-004802 | 276902 | ||||||
| 2020-09-25 | CORRESP | filename1.htm | 0001193125-20-254770 | 46005 | ||||||
| 2020-09-25 | S-1 | S-1 | 0001193125-20-254760 | 333-249077 | 201201105 | 33 | 11002837 | |||
| 2020-09-23 | UPLOAD | filename1.pdf | 0000000000-20-008935 | 52334 | ||||||
| 2020-08-26 | DRS | filename1.htm | 0000950123-20-009341 | 377-03456 | 201134018 | 33 | 6018792 | |||
| 2020-01-16 | D | xslFormDX01/primary_doc.xml | 06b | 0001567619-20-001131 | 021-358226 | 20530066 | 33 | 16555 |
One latest value per concept from companyfacts (251 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 42.61M | 2021-08-04 | 2021 | Q2 | 10-Q | 2021-08-05 | 0001564590-21-041653 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 19.90M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 252.72 | 2026-08-04 | S-8 | 2026-08-06 | 0001193125-26-337937 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 252.72 | 2026-08-04 | S-8 | 2026-08-06 | 0001193125-26-337937 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 1.83M | 2026-08-04 | S-8 | 2026-08-06 | 0001193125-26-337937 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-08-04 | S-8 | 2026-08-06 | 0001193125-26-337937 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 3.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 27.78M | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-06 | 0001193125-26-336851 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 491,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 15.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AccruedRoyaltiesCurrentAndNoncurrent | Accrued Royalties | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 13.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | 437,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 699.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition | USD | 108,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition | USD | 1.17M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 9.26M | 2021-01-01 | 2021-09-30 | 2022 | Q3 | 10-Q | 2022-11-02 | 0000950170-22-021248 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 3.66M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs | USD | -875,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 3.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 6.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | Assets | Assets | USD | 47.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 34.68M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 1,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 39.56M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 | |
| us-gaap | AvailableForSaleSecuritiesAndHeldToMaturitySecurities | Available-for-sale Securities and Held-to-maturity Securities | USD | 23.14M | 2020-12-31 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | USD | 39.56M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | USD | 39.59M | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 0 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 | |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 15,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 31.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | CashCashEquivalentsAndShortTermInvestments | Cash, Cash Equivalents, and Short-term Investments | USD | 54.90M | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-07 | 0001193125-26-212001 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 31.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | USD | 13.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights | Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 134,112 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 115.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 6.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 6.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 9,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -46.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ContractWithCustomerLiabilityCurrent | Contract with Customer, Liability, Current | USD | 7.89M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | ContractWithCustomerLiabilityNoncurrent | Contract with Customer, Liability, Noncurrent | USD | 4.11M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | ContractWithCustomerLiabilityRevenueRecognized | Contract with Customer, Liability, Revenue Recognized | USD | 5.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 238.52M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue | Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value | USD | 3.17M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | CurrentForeignTaxExpenseBenefit | Current Foreign Tax Expense (Benefit) | USD | 314,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 314,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 1,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | DebtInstrumentConvertibleBeneficialConversionFeature | Debt Instrument, Convertible, Beneficial Conversion Feature | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction | Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction | USD | 405,000 | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | DebtSecuritiesAvailableForSaleAllowanceForCreditLoss | Debt Securities, Available-for-sale, Allowance for Credit Loss | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DebtSecuritiesAvailableForSaleAndHeldToMaturity | Debt Securities, Available-for-sale and Held-to-maturity | USD | 19.03M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions | Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | Investment | 0 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | DeferredFinanceCostsNet | Debt Issuance Costs, Net | USD | 442,000 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 1.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsDeferredIncome | Deferred Tax Assets, Deferred Income | USD | 24,000 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 82.33M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 1.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsDomestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | USD | 29.98M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsForeign | Deferred Tax Assets, Operating Loss Carryforwards, Foreign | USD | 33,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | USD | 10.66M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 806,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 4.66M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 1.70M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other | USD | 1.62M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 81.28M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DeferredTaxLiabilitiesPropertyPlantAndEquipment | Deferred Tax Liabilities, Property, Plant and Equipment | USD | 142,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | DefinedContributionPlanEmployerDiscretionaryContributionAmount | Defined Contribution Plan, Employer Discretionary Contribution Amount | USD | 700,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | DefinedContributionPlanEmployerMatchingContributionPercent | Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | pure | 0.018 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | Depreciation | Depreciation | USD | 852,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | DerivativeGainLossOnDerivativeNet | Derivative, Gain (Loss) on Derivative, Net | USD | -296,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | DerivativeLiabilitiesNoncurrent | Derivative Liability, Noncurrent | USD | 461,000 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 | |
| us-gaap | DividendsCommonStockCash | Dividends, Common Stock, Cash | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -4.45 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -2.25 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -4.45 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.013 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.742 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.038 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0.002 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | -0.053 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxSettlementsForeign | Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent | pure | -0.003 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 5.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 3,000 | 2024-01-31 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 | |
| us-gaap | EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense | Share-based Payment Arrangement, Expense, Tax Benefit | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | FairValueAdjustmentOfWarrants | Fair Value Adjustment of Warrants | USD | -6.56M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | FinanceLeaseInterestExpense | Finance Lease, Interest Expense | USD | 5,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | FinanceLeaseLiability | Finance Lease, Liability | USD | 145,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | FinanceLeaseLiabilityCurrent | Finance Lease, Liability, Current | USD | 59,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | FinanceLeaseLiabilityNoncurrent | Finance Lease, Liability, Noncurrent | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDue | Finance Lease, Liability, Payment, Due | USD | 144,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueNextTwelveMonths | Finance Lease, Liability, to be Paid, Year One | USD | 144,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearFive | Finance Lease, Liability, to be Paid, Year Five | USD | 51,000 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearFour | Finance Lease, Liability, to be Paid, Year Four | USD | 42,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearThree | Finance Lease, Liability, to be Paid, Year Three | USD | 44,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-12 | 0000950170-24-029953 | |
| us-gaap | FinanceLeaseLiabilityPaymentsDueYearTwo | Finance Lease, Liability, to be Paid, Year Two | USD | 42,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 | |
| us-gaap | FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear | Finance Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 19,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 | |
| us-gaap | FinanceLeaseLiabilityUndiscountedExcessAmount | Finance Lease, Liability, Undiscounted Excess Amount | USD | 20,000 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 | |
| us-gaap | FinanceLeasePrincipalPayments | Finance Lease, Principal Payments | USD | 86,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | FinanceLeaseRightOfUseAsset | Finance Lease, Right-of-Use Asset, after Accumulated Amortization | USD | 296,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | FinanceLeaseRightOfUseAssetAccumulatedAmortization | Finance Lease, Right-of-Use Asset, Accumulated Amortization | USD | 500,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization | Finance Lease, Right-of-Use Asset, before Accumulated Amortization | USD | 700,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | FinanceLeaseWeightedAverageDiscountRatePercent | Finance Lease, Weighted Average Discount Rate, Percent | pure | 0.056 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | 200,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | GainLossOnDispositionOfAssets1 | Gain (Loss) on Disposition of Assets | USD | -17,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 |
| us-gaap | GainLossOnSaleOfInvestments | Gain (Loss) on Sale of Investments | USD | -57,000 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | GainOnSaleOfInvestments | Gain on Sale of Investments | USD | 68,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 17.89M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | GovernmentAssistanceAmount | GovernmentAssistanceAmount | USD | 11.30M | 2025-04-01 | 2025-04-30 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | HeldToMaturitySecurities | Debt Securities, Held-to-maturity | USD | 19.07M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain | Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain | USD | 188,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss | Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss | USD | 0 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue | Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | USD | 3.92M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount | Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | USD | 3.92M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | HeldToMaturitySecuritiesFairValue | Debt Securities, Held-to-maturity, Fair Value | USD | 19.03M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | ImpairmentOfInvestments | Other than Temporary Impairment Losses, Investments | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-12 | 0000950170-24-029953 |
| us-gaap | ImpairmentOfLongLivedAssetsHeldForUse | Impairment of Long-Lived Assets Held-for-use | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -20.77M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -42.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | -3.11M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | -90.42M | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 |
| us-gaap | IncomeTaxesPaid | Income Taxes Paid | USD | 1,000 | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 315,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 3.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 17.72M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeTaxReconciliationDeductionsOther | Effective Income Tax Rate Reconciliation, Deduction, Other, Amount | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014872 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -5.01M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 1,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 896,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 1.25M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | -768,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 27.78M | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-06 | 0001193125-26-336851 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 1.62M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | IncreaseDecreaseInContractWithCustomerLiability | Increase (Decrease) in Contract with Customer, Liability | USD | -569,000 | 2024-01-01 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 |
| us-gaap | IncreaseDecreaseInDeferredRevenue | Increase (Decrease) in Deferred Revenue | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | IncreaseDecreaseInOtherCurrentAssets | Increase (Decrease) in Other Current Assets | USD | -2.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | IncreaseDecreaseInOtherOperatingLiabilities | Increase (Decrease) in Other Operating Liabilities | USD | -47,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | InterestIncomeExpenseNet | Interest Income (Expense), Net | USD | 600,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | InterestPaid | Interest Paid, Including Capitalized Interest, Operating and Investing Activities | USD | 4,000 | 2020-01-01 | 2020-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 |
| us-gaap | Investments | Investments | USD | 0 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-12 | 0000950170-24-029953 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 5.42M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 1.11M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 3.83M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 161,000 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-12 | 0000950170-24-029953 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 155,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 174,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 1.42M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 704,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 311,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | Liabilities | Liabilities | USD | 35.88M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 47.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 19.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | LongTermInvestments | Long-term Investments | USD | 15.11M | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 | |
| us-gaap | LongTermPurchaseCommitmentAmount | Long-term Purchase Commitment, Amount | USD | 4.50M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 |
| us-gaap | LossContingencyAccrualAtCarryingValue | Loss Contingency Accrual | USD | 0 | 2023-06-30 | 2023 | Q2 | 10-Q | 2023-08-03 | 0000950170-23-038045 | |
| us-gaap | MinorityInterestChangeInRedemptionValue | Noncontrolling Interest, Change in Redemption Value | USD | -11.39M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 150,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 59.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -46.63M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -46.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2026-01-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-06 | 0001193125-26-336851 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | Segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 84.19M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -50.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 2.46M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | OperatingLeaseImpairmentLoss | Operating Lease, Impairment Loss | USD | 724,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 5.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 1.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 10.66M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 3.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 11.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 1.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.088 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 4.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 2.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 268,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent | USD | 5,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | USD | -31,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | USD | -31,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 133,000 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-02 | 0000950170-22-021248 | |
| us-gaap | OtherOperatingIncomeExpenseNet | Other Operating Income (Expense), Net | USD | 1.20M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | PaymentOfFinancingAndStockIssuanceCosts | Payment of Financing and Stock Issuance Costs | USD | 405,000 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | PaymentsToAcquireAvailableForSaleSecuritiesDebt | Payments to Acquire Debt Securities, Available-for-sale | USD | 45.28M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 |
| us-gaap | PaymentsToAcquireHeldToMaturitySecurities | Payments to Acquire Held-to-maturity Securities | USD | 0 | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 |
| us-gaap | PaymentsToAcquireLongtermInvestments | Payments to Acquire Long-term Investments | USD | 16.39M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 130,000 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 |
| us-gaap | PaymentsToAcquireShortTermInvestments | Payments to Acquire Short-term Investments | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 23,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 40.00M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | ProceedsFromIssuanceOfWarrants | Proceeds from Issuance of Warrants | USD | 86.20M | 2023-10-01 | 2023-10-31 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments | Proceeds from Sale, Maturity and Collection of Short-term Investments | USD | 60.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ProceedsFromSaleOfAvailableForSaleSecuritiesDebt | Proceeds from Sale of Debt Securities, Available-for-sale | USD | 45.01M | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-02 | 0000950170-23-058256 |
| us-gaap | ProceedsFromSaleOfHeldToMaturitySecurities | Proceeds from Sale of Held-to-maturity Securities | USD | 10.00M | 2021-01-01 | 2021-09-30 | 2022 | Q3 | 10-Q | 2022-11-02 | 0000950170-22-021248 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 23,000 | 2023-01-01 | 2023-09-30 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 236,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ProceedsFromWarrantExercises | Proceeds from Warrant Exercises | USD | 1.13M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 14.78M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 1.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | PurchaseObligation | Purchase Obligation | USD | 4.10M | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-04 | 0001564590-21-054514 | |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 66.29M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 110,000 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 645,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -688.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 5.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability | USD | 284,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 9.35M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 3.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 1.79M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 19.89M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 12.86M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | USD | 24.55M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | SharePrice | Share Price | USD/shares | 650 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-25 | 0001193125-20-303749 | |
| us-gaap | ShortTermInvestments | Short-term Investments | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | ShortTermLeaseCost | Short-term Lease, Cost | USD | 89,000 | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 11.31M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.04 | 2024-08-19 | 2024 | Q3 | 10-Q | 2024-11-06 | 0000950170-24-122371 | |
| us-gaap | StockIssuedDuringPeriodSharesReverseStockSplits | Stock Issued During Period, Shares, Reverse Stock Splits | shares | 3.30M | 2024-08-19 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 236,000 | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 78.58M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | USD | 2,000 | 2025-07-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-06 | 0001193125-25-268203 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 23,000 | 2023-01-01 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-10 | 0000950170-25-035929 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 100.69M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 10.00M | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 0 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 10.82M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 1.45M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 842,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-10 | 0000950170-22-003365 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 687,000 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 24.80M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 10.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 42.70M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-09 | 0000950170-23-007033 |
| us-gaap | WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation | Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation | shares | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-05 | 0001193125-26-092614 |
| us-gaap | WeightedAverageNumberOfSharesContingentlyIssuable | Weighted Average Number of Shares, Contingently Issuable | shares | 0 | 2025-01-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 10.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-06 | 0001193125-26-450798 |